What is Sooma?
Sooma Medical specializes in the development and distribution of innovative brain stimulation treatments, primarily targeting depression and chronic pain. Its flagship product, Sooma tDCS, offers a non-invasive, drug-free alternative for patients, providing healthcare professionals with a highly efficient tool for symptom management. With a footprint spanning over 35 countries, the company has established itself as a global leader in the tDCS space, supported by rigorous clinical validation and a commitment to improving patient outcomes through accessible, safe, and evidence-based technology.
How much funding has Sooma raised?
Sooma has raised a total of $6.9M across 2 funding rounds:
Unspecified
$1.4M
Other Financing Round
$5.5M
Unspecified (2019): $1.4M with participation from Business Finland
Other Financing Round (2024): $5.5M led by Voima Ventures
Key Investors in Sooma
Voima Ventures
Voima Ventures is a Nordic-based VC firm specializing in scientific deep tech, focusing on scaling innovations that address global challenges through science-driven entrepreneurship.
Business Finland
A government-backed organization that provides funding and strategic support to Finnish companies, fostering international growth and innovation.
What's next for Sooma?
With the recent capital injection, Sooma is well-positioned to scale its operations and deepen its market penetration. The company is expected to focus on expanding its clinical research initiatives and enhancing its distribution networks to meet the rising global demand for non-pharmacological mental health solutions. As the firm moves into this next phase of growth, the focus will likely shift toward optimizing patient care pathways and integrating its technology into standard clinical practice, thereby reinforcing its competitive advantage in the neurotech landscape.
See full Sooma company page
